Laura Hou

510 total citations
19 papers, 275 citations indexed

About

Laura Hou is a scholar working on Epidemiology, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Laura Hou has authored 19 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 5 papers in Cardiology and Cardiovascular Medicine and 3 papers in Surgery. Recurrent topics in Laura Hou's work include Inflammatory Bowel Disease (3 papers), Microscopic Colitis (3 papers) and Atrial Fibrillation Management and Outcomes (2 papers). Laura Hou is often cited by papers focused on Inflammatory Bowel Disease (3 papers), Microscopic Colitis (3 papers) and Atrial Fibrillation Management and Outcomes (2 papers). Laura Hou collaborates with scholars based in United States, Canada and Denmark. Laura Hou's co-authors include Nathaniel C. Wingert, Robert L. Parisien, Paul H. Yi, Andrew Jawa, Elie Ghanem, Xinning Li, Sengwee Toh, Ting‐Ying Huang, Kevin Haynes and Shirley Poon and has published in prestigious journals such as American Journal of Epidemiology, Environmental Health Perspectives and Clinical Orthopaedics and Related Research.

In The Last Decade

Laura Hou

17 papers receiving 273 citations

Peers

Laura Hou

SURGE

EPIDE

CCM

HTM

Neha Garg India

Nehal El‐Koofy Egypt

Sara Tehrani Sweden

Anna Warnqvist Sweden

Rajko Ostojić Croatia

Fabian J. Brunner Germany

Xuewei Huang China

A. Kottgen United States

Dhruvil Radadiya United States

Emilia Sawicka Poland

Neha Garg India

Laura Hou

96 ×0.8

SURGE

39 ×0.6

EPIDE

146 ×2.6

CCM

51 ×1.5

HTM

16 ×0.8

Citations per year, relative to Laura Hou Laura Hou (= 1×) peers Neha Garg

Countries citing papers authored by Laura Hou

Since Specialization

Citations

This map shows the geographic impact of Laura Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Hou more than expected).

Fields of papers citing papers by Laura Hou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Hou. The network helps show where Laura Hou may publish in the future.

Co-authorship network of co-authors of Laura Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Hou. A scholar is included among the top collaborators of Laura Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Hou. Laura Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Zou, Guangyong, Laura Hou, Andrew B. Petrone, et al.. (2024). A simple Cox approach to estimating risk ratios without sharing individual-level data in multisite studies. American Journal of Epidemiology. 194(1). 226–232.

Chen, Cheng, Efe Eworuke, Ashish Rai, et al.. (2024). Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk. Pharmacoepidemiology and Drug Safety. 33(10). e70040–e70040.

Eworuke, Efe, Mayura Shinde, Laura Hou, et al.. (2024). Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark. Pharmacoepidemiology and Drug Safety. 33(9). e5849–e5849. 1 indexed citations

Eworuke, Efe, Mayura Shinde, Laura Hou, et al.. (2023). Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study. BMJ Open. 13(4). e070985–e070985. 13 indexed citations

Long, Millie D., Lauren E. Parlett, James D. Lewis, et al.. (2023). Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 30(8). 1345–1352. 4 indexed citations

Adimadhyam, Sruthi, James D. Lewis, Andrew Simon, et al.. (2023). Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis. Inflammatory Bowel Diseases. 30(4). 554–562. 2 indexed citations

Lu, Christine Y., et al.. (2022). A new analytic tool for assessing the impact of the US Food and Drug Administration regulatory actions. Pharmacoepidemiology and Drug Safety. 32(3). 298–311. 4 indexed citations

Kappelman, Michael D., Sruthi Adimadhyam, Laura Hou, et al.. (2022). Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease. The American Journal of Gastroenterology. 118(4). 674–684. 11 indexed citations

Eworuke, Efe, Laura Hou, Rongmei Zhang, et al.. (2021). Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin. Drug Safety. 44(7). 753–763. 6 indexed citations

10.

Epstein, Mara M., Sarah K. Dutcher, Judith C. Maro, et al.. (2021). Validation of an electronic algorithm for Hodgkin and non‐Hodgkin lymphoma in ICD‐10‐CM. Pharmacoepidemiology and Drug Safety. 30(7). 910–917. 5 indexed citations

11.

Kluberg, Sheryl A., Laura Hou, Sarah K. Dutcher, et al.. (2021). Validation of diagnosis codes to identify hospitalized COVID‐19 patients in health care claims data. Pharmacoepidemiology and Drug Safety. 31(4). 476–480. 32 indexed citations

12.

Webster‐Clark, Michael, Ting‐Ying Huang, Laura Hou, & Sengwee Toh. (2020). Translating claims‐based CHA₂DS₂‐VaSc and HAS‐BLED to ICD‐10‐CM: Impacts of mapping strategies. Pharmacoepidemiology and Drug Safety. 29(4). 409–418. 12 indexed citations

13.

Carnahan, Ryan M., Joshua J. Gagne, Christian Hampp, et al.. (2019). Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users. Pharmaceutical Medicine. 33(1). 29–43. 6 indexed citations

14.

Izem, Rima, et al.. (2019). Quantifying how small variations in design elements affect risk in an incident cohort study in claims. Pharmacoepidemiology and Drug Safety. 29(1). 84–93. 2 indexed citations

15.

Ouyang, Chensi, Marina Frimer, Laura Hou, et al.. (2018). Malignant Endometrial Polyps in Uterine Serous Carcinoma. International Journal of Gynecological Cancer. 28(3). 524–528. 6 indexed citations

16.

Goodyer, Cynthia G., Shirley Poon, Katarina Aleksa, et al.. (2017). A Case–Control Study of Maternal Polybrominated Diphenyl Ether (PBDE) Exposure and Cryptorchidism in Canadian Populations. Environmental Health Perspectives. 125(5). 39001–39001. 40 indexed citations

17.

Wingert, Nathaniel C., et al.. (2016). The ACS NSQIP Risk Calculator Is a Fair Predictor of Acute Periprosthetic Joint Infection. Clinical Orthopaedics and Related Research. 474(7). 1643–1648. 68 indexed citations

18.

Parisien, Robert L., Paul H. Yi, Laura Hou, Xinning Li, & Andrew Jawa. (2016). The risk of nerve injury during anatomical and reverse total shoulder arthroplasty: an intraoperative neuromonitoring study. Journal of Shoulder and Elbow Surgery. 25(7). 1122–1127. 53 indexed citations

19.

Bern, Murray M., Daniel M. Ward, Damon J. Spitz, et al.. (2015). Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study. Thrombosis Journal. 13(1). 32–32. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact